{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:58:58Z","timestamp":1787065138040,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Medical Research Agency","doi-asserted-by":"crossref","award":["2023\/ABM\/01\/00040"],"award-info":[{"award-number":["2023\/ABM\/01\/00040"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023181","name":"Medical Research Agency","doi-asserted-by":"crossref","award":["2023\/ABM\/01\/00040"],"award-info":[{"award-number":["2023\/ABM\/01\/00040"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023181","name":"Medical Research Agency","doi-asserted-by":"crossref","award":["2023\/ABM\/01\/00040"],"award-info":[{"award-number":["2023\/ABM\/01\/00040"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13552-y","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:58:32Z","timestamp":1737698312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"\u0141ukasz","family":"Kuncman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Fijuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Tworek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Sierko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Cisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mas\u0142owski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Orzechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Galwas-Kliber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Antczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Chmielewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zi\u00f3\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kurczewska-Michalak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Ku\u017anicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"J\u0119drzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Ranoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Bilski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"3","key":"13552_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"13552_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primer. 2021;7(1):3.","journal-title":"Nat Rev Dis Primer."},{"issue":"23","key":"13552_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"13552_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365.","journal-title":"Lancet Oncol"},{"issue":"9962","key":"13552_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, Van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36\u201342.","journal-title":"Lancet"},{"issue":"10","key":"13552_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017;12(10):1561\u201370.","journal-title":"J Thorac Oncol"},{"key":"13552_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Small Cell Lung Cancer Version 3.2025 \u2014 October 29, 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Cited 2024 Dec 21."},{"key":"13552_CR8","doi-asserted-by":"crossref","unstructured":"Kitala, Diana et al. Medical research agency: 5 years of reshaping the clinical trials ecosystem in Poland.\u00a0Lancet Reg Health Eur. 48:101175.","DOI":"10.1016\/j.lanepe.2024.101175"},{"issue":"12","key":"13552_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441\u201364.","journal-title":"J Natl Compr Canc Netw."},{"key":"13552_CR10","doi-asserted-by":"publisher","first-page":"109966","DOI":"10.1016\/j.radonc.2023.109966","volume":"190","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger M, Andratschke N, Belka C, Bellut D, Cuccia F, Dahele M, et al. ESTRO clinical practice guideline: stereotactic body radiotherapy for spine metastases. Radiother Oncol. 2024;190:109966.","journal-title":"Radiother Oncol"},{"issue":"3","key":"13552_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","volume":"10","author":"CB Simone","year":"2020","unstructured":"Simone CB, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10(3):158\u201373.","journal-title":"Pract Radiat Oncol"},{"key":"13552_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","volume":"152","author":"C Le Pechoux","year":"2020","unstructured":"Le Pechoux C, Faivre-Finn C, Ramella S, McDonald F, Manapov F, Putora PM, et al. ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiother Oncol. 2020;152:89\u201395.","journal-title":"Radiother Oncol"},{"key":"13552_CR13","unstructured":"Respiratory small cell lung cancer thoracic EBRT with or without chemotherapy 2023 V.1), , eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 29th October 2024, https:\/\/www.eviq.org.au\/radiation-oncology\/respiratory\/4292-respiratory-small-cell-lung-cancer-thoracic-e#organs-at-risk."},{"issue":"1","key":"13552_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A story of hypofractionation and the table on the wall. Int J Radiat Oncol Biol Phys. 2022;112(1):4\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10212","key":"13552_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"issue":"2","key":"13552_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4143\/crt.2023.931","volume":"56","author":"D Kim","year":"2024","unstructured":"Kim D, Kim HJ, Wu HG, Lee JH, Kim S, Kim TM, et al. Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: implications for thoracic radiotherapy. Cancer Res Treat. 2024;56(2):430\u201341.","journal-title":"Cancer Res Treat"},{"issue":"13","key":"13552_CR17","doi-asserted-by":"publisher","first-page":"22251","DOI":"10.18632\/oncotarget.14759","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yu J, Zhu H, Meng X, Li M, Jiang L, et al. Consolidative thoracic radiotherapy for extensive stage small cell lung cancer. Oncotarget. 2017;8(13):22251\u201361.","journal-title":"Oncotarget"},{"key":"13552_CR18","doi-asserted-by":"publisher","first-page":"1426635","DOI":"10.3389\/fimmu.2024.1426635","volume":"15","author":"\u0141 Kuncman","year":"2024","unstructured":"Kuncman \u0141, Pajdzi\u0144ski M, Sm\u00f3\u0142ka K, Bilski M, Socha J, Stando R, et al. Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer. Front Immunol. 2024;15:1426635.","journal-title":"Front Immunol"},{"key":"13552_CR19","doi-asserted-by":"crossref","unstructured":"Walls GM, Bergom C, Mitchell JD, Rentschler SL, Hugo GD, Samson PP, et al. Cardiotoxicity following thoracic radiotherapy for lung cancer. Br J Cancer . 2024; Available from: https:\/\/www.nature.com\/articles\/s41416-024-02888-0. Cited 2024 Dec 23.","DOI":"10.1038\/s41416-024-02888-0"},{"issue":"24","key":"13552_CR20","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.3390\/cancers13246193","volume":"13","author":"JY Jin","year":"2021","unstructured":"Jin JY, Hu C, Xiao Y, Zhang H, Paulus R, Ellsworth SG, et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: A secondary analysis of RTOG0617. Cancers. 2021;13(24):6193.","journal-title":"Cancers"},{"issue":"10","key":"13552_CR21","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","volume":"15","author":"A Abravan","year":"2020","unstructured":"Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, Van Herk M. Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer. J Thorac Oncol. 2020;15(10):1624\u201335.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"13552_CR22","first-page":"100391","volume":"3","author":"W Jing","year":"2022","unstructured":"Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, et al. Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022;3(9):100391.","journal-title":"JTO Clin Res Rep"},{"key":"13552_CR23","unstructured":"NRG-LU007: The RAPTOR Study for ES-SCLC. Available from: https:\/\/www.nrgoncology.org\/RAPTOR. Cited 2024 Dec 21."},{"issue":"1","key":"13552_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1186\/s12885-022-10074-9","volume":"22","author":"F Bozorgmehr","year":"2022","unstructured":"Bozorgmehr F, Christopoulos P, Chung I, Cvetkovic J, Fei\u00dft M, Krisam J, et al. Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease \u2013 a randomized, open-label, multicenter phase II trial. BMC Cancer. 2022;22(1):1011.","journal-title":"BMC Cancer"},{"issue":"1","key":"13552_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/1759-7714.14727","volume":"14","author":"H Ishii","year":"2023","unstructured":"Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N, et al. Phase II study of durvalumab ( MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: study protocol of turtle study ( LOGIK 2003). Thorac Cancer. 2023;14(1):105\u20137.","journal-title":"Thorac Cancer"},{"key":"13552_CR26","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.radonc.2024.110466","volume":"199","author":"F Alongi","year":"2024","unstructured":"Alongi F, Nicosia L, Ricardi U, Scorsetti M, Greto D, Balermpas P, et al. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: an interim analysis of the E2-RADIatE OligoCare cohort. Radiother Oncol. 2024;199:110466.","journal-title":"Radiother Oncol"},{"issue":"1","key":"13552_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13014-024-02420-x","volume":"19","author":"Y Yao","year":"2024","unstructured":"Yao Y, Li B, Song R, Yang L, Zou B, Wang L. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis. Radiat Oncol. 2024;19(1):25.","journal-title":"Radiat Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13552-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:58:36Z","timestamp":1737698316000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13552"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13552-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research complies with the Helsinki Declaration and has been approved by Medical University of Lodz Ethics committee.Trial registration: Clinicaltrials.gov identifier: NCT06529081; Registered 26 July 2024. A signature of the informed consent will be obtained from all patients before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No patient-level information in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}